Veracyte, Inc. (VCYT)
44.65
-3.02
(-6.34%)
USD |
NASDAQ |
Oct 06, 16:00
44.65
0.00 (0.00%)
After-Hours: 05:51
Veracyte Enterprise Value : 3.143B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 3.143B |
| October 05, 2026 | 3.386B |
| October 02, 2026 | 3.236B |
| October 01, 2026 | 3.106B |
| September 30, 2026 | 3.255B |
| September 29, 2026 | 3.258B |
| September 28, 2026 | 3.190B |
| September 25, 2026 | 3.206B |
| September 24, 2026 | 3.456B |
| September 23, 2026 | 3.076B |
| September 22, 2026 | 3.039B |
| September 21, 2026 | 2.892B |
| September 18, 2026 | 2.753B |
| September 17, 2026 | 2.815B |
| September 16, 2026 | 2.649B |
| September 15, 2026 | 2.781B |
| September 14, 2026 | 2.867B |
| September 11, 2026 | 2.839B |
| September 10, 2026 | 2.933B |
| September 09, 2026 | 3.080B |
| September 08, 2026 | 2.966B |
| September 04, 2026 | 2.973B |
| September 03, 2026 | 3.145B |
| September 02, 2026 | 3.162B |
| September 01, 2026 | 3.045B |
| Date | Value |
|---|---|
| August 31, 2026 | 3.026B |
| August 28, 2026 | 3.038B |
| August 27, 2026 | 3.191B |
| August 26, 2026 | 3.114B |
| August 25, 2026 | 3.094B |
| August 24, 2026 | 2.888B |
| August 21, 2026 | 2.955B |
| August 20, 2026 | 2.913B |
| August 19, 2026 | 2.945B |
| August 18, 2026 | 2.824B |
| August 17, 2026 | 2.937B |
| August 14, 2026 | 2.870B |
| August 13, 2026 | 2.978B |
| August 12, 2026 | 3.146B |
| August 11, 2026 | 3.285B |
| August 10, 2026 | 3.273B |
| August 07, 2026 | 3.350B |
| August 06, 2026 | 3.264B |
| August 05, 2026 | 3.264B |
| August 04, 2026 | 3.285B |
| August 03, 2026 | 3.159B |
| July 31, 2026 | 3.277B |
| July 30, 2026 | 4.359B |
| July 29, 2026 | 4.032B |
| July 28, 2026 | 4.027B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ionis Pharmaceuticals, Inc. | 7.422B |
| Quantum Cyber NV | 27.87M |
| bioAffinity Technologies, Inc. | 1.746M |
| Recursion Pharmaceuticals, Inc. | 1.989B |
| Karyopharm Therapeutics, Inc. | 205.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 25.49M |
| Revenue (Quarterly) | 150.32M |
| Total Expenses (Quarterly) | 124.83M |
| EPS Diluted (Quarterly) | 0.3106 |
| Gross Profit Margin (Quarterly) | 71.93% |
| Profit Margin (Quarterly) | 16.96% |
| Earnings Yield | 3.16% |
| Operating Earnings Yield | 2.67% |
| Normalized Earnings Yield | 2.889 |